NCT04101812 - Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 17, 2019

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2021

Conditions

Muscle Invasive Bladder Cancer

Interventions

DRUG

pegylated liposomal doxorubicin (PLD)

PLD is an anthracycline topoisomerase II inhibitor that is encapsulated in liposomes for intravenous use.

DRUG

PD-1

PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands and PD-L1.

Trial Locations (1)

Unknown

RECRUITING

Tianjin Medical Unversity Second Hospital, Tianjin